Patent Law Weblog

recent posts

about

Sanofi Licenses Cancer Drug

    By Jason Derry —

Oxford_biomedica
Sanofi-Aventis and Oxford BioMedica have announced an agreement under which the two companies will jointly develop and market TroVax® for treating and preventing cancer.  TroVax® is a gene-based therapeutic cancer vaccine, and is currently in Phase III clinical trials as a treatment for renal cancer.  Under the terms of the agreement, Sanofi will pay Oxford BioMedica an upfront fee of $39 million, with additional $25 million payments as targets are hit.  The potential payout for Oxford BioMedica is $690 million.

Sanofiaventis_3

Posted in

One response to “Sanofi Licenses Cancer Drug”

  1. Dr Jeff Aitkin Avatar
    Dr Jeff Aitkin

    My friends father died of Asbestos related illness and cancer. I inspired me to delve into the available research and information on how these terrible events might be avoided or life extended.
    From what i have read of the published medical data and research, particularly that conducted in China and Japan there is a great deal of evidence to support complimentary immune therapy, especially with infections and cancer. I’ve been following with some interest the development of a complimentary cancer treatment that has been designed in liason with the University of Newcastle (Australia) and although a somewhat different approach to the above outlined treatment the concept and the deliberate and effective use of natural elements in the product are similar. If you have an interest in this field or perhaps just want to keep abreast of a new treatment you may find http://www.mc-s.com.au fairly worthwhile reviewing.

    Like

    Reply

Leave a reply to Dr Jeff Aitkin Cancel reply